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Purpose
Currently, there is significant variability in the therapeu-
tic approaches to new onset systemic Juvenile Idiopathic
Arthritis (sJIA), as evidenced by surveys using case pre-
sentations administered to Childhood Arthritis and
Rheumatology Research Alliance (CARRA) members.
Understanding the comparative effectiveness of these
diverse therapeutic approaches would likely result in bet-
ter health outcomes. We therefore aimed to derive con-
sensus based treatment plans, standardized assessment
intervals and data collection plans for clinical use to facil-
itate comparative effectiveness studies for new-onset
sJIA. Eligible patients may be enrolled into any of the
treatment plans at the treating physician’s discretion.
Methods
To develop eligibility criteria and consensus approaches to
therapeutic management, the CARRA sJIA Core Work-
group convened regularly for workgroup meetings, hosted
a 2-day CARRA consensus conference in April 2010, and
conducted surveys of the CARRA membership.
Results
The CARRA sJIA Core Workgroup developed formal elig-
ibility criteria for patient enrollment, standardized treat-
ment approaches, and a recommended schedule of visits
and monitoring parameters. Entry criteria include age 6m-
18y and probable sJIA determined by defined criteria. The
treatment regimens include: 1) a corticosteroid based plan,
2) a methotrexate based plan – with/without corticoster-
oid, and 3) an anti-IL1 (anakinra) based plan – with/
without corticosteroid. A survey of the CARRA member-
ship was conducted in December 2010 to assess the
acceptability and feasibility of these strategies. There was a
63% response rate (133 of 211 surveyed), of which 92.6%
expressed willingness to follow 1 of 3 treatment plans as
outlined. 82% concurred that a 4th anti-IL6 based treat-
ment arm should also be offered. Consensus was reached
at the 78-85% level for all topics posed (entry criteria,
specific details of treatment plans, ability to use plans). A
feasibility study estimated that over 250 patients could be
enrolled in these plans per year, and that physicians would
likely enroll one-third to one-quarter of the patients in
each of the original 3 plans.
Conclusion
The use of consensus derived standardized treatment
plans for new onset SJIA is feasible and acceptable to
most North American rheumatologists who are mem-
bers of CARRA. Four treatment approaches to the first
6 months of treatment will be published as frameworks
for use. Coupled with standardized data collection at
routine intervals, use of these treatment plans will serve
as the basis for rigorous study of comparative effective-
ness of the regimens as used in clinical practice.
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